Disposition of lorazepam in diabetes: differences between patients treated with beef/pork and human insulins.
The pharmacokinetics of lorazepam was examined in 10 male patients with insulin-dependent diabetes mellitus before and following treatment with neomycin and cholestyramine. Neomycin and cholestyramine were given in an attempt to block the enterohepatic circulation of lorazepam and so to permit an in vivo estimate of hepatic glucuronidation. The volume of distribution and clearance of free lorazepam in diabetic patients were not significantly different from the corresponding estimates in 14 normal controls. Neomycin and cholestyramine increased the clearance of lorazepam by 63% consistent with their effect in non-diabetic controls. However, patients on beef/pork insulin exhibited a greater than normal increase on this interupting regimen (125%), and had a significantly greater neomycin/cholestyramine cycling-interrupted clearance of lorazepam than either normal controls or patients on human insulin (15.4 vs. 6.96 and 7.87 ml.min-1.kg-1). The clearance was correlated positively and significantly with HbA1c and glycated proteins (fructosamine), but only in patients on human insulin. Thus, the pharmacokinetics of lorazepam was not altered in patients with insulin-dependent diabetes mellitus. However, it is possible that there are differences in the rate and extent of hepatic glucuronidation and enterohepatic circulation of lorazepam between patients treated with beef/pork and human insulins and between diabetics treated with beef/pork insulin and non-diabetic controls.
Herman
R J
RJ
Department of Medicine, Royal University Hospital, University of Saskatchewan, Saskatoon, Canada.
Chaudhary
A
A
Szakacs
C B
CB
Woo
D
D
Lane
R
R
Boctor
M A
MA
D000293:Adolescent; D000328:Adult; D002792:Cholestyramine Resin / Q000493:pharmacokinetics; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D006801:Humans; D007328:Insulin / Q000494:pharmacology* / Q000627:therapeutic use*; D008140:Lorazepam / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D008297:Male; D009355:Neomycin / Q000493:pharmacokinetics; D010599:Pharmacokinetics
D007328:Insulin; D002792:Cholestyramine Resin; D009355:Neomycin; D008140:Lorazepam